Charles River Laboratories International, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter ended September 30, 2023; comparisons are with the quarter ended September 24, 2022. The nine-month period is compared with the nine months ended September 24, 2022. Amounts below are in millions, except per-share data.
Business context
Charles River provides research models and services, drug discovery and safety assessment, and manufacturing solutions to pharmaceutical, biotechnology, and other life-sciences clients. Its reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
Financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $1,026.6 | $989.2 | $3,115.9 | $2,876.2 |
| Operating income | $151.5 | $151.0 | $484.3 | $487.2 |
| Operating margin | 14.8% | 15.3% | 15.5% | 16.9% |
| Net income attributable to common shareholders | $87.4 | $96.5 | $287.5 | $298.8 |
| Diluted EPS | $1.69 | $1.88 | $5.58 | $5.83 |
| Interest expense | $33.7 | $11.4 | $103.2 | $24.5 |
Quarterly revenue grew 3.8% (service revenue +7.0%; product revenue −11.0%). Nine-month revenue grew 8.3% (service +12.3%; product −8.2%). Higher Safety Assessment activity and pricing supported service growth; lower product revenue and the Avian divestiture weighed on results. Operating margin declined 50 basis points in Q3 and 140 basis points for the nine-month period. Higher variable-rate borrowing costs contributed to lower net income and EPS.
Cash flow and liquidity: Nine-month operating cash flow was $463.0, versus $384.9 a year earlier; capital expenditures were $240.2. Investing cash outflow was $324.8 and financing cash outflow was $209.1. Cash and equivalents were $157.2 at September 30, 2023, down from $233.9 at year-end 2022. Long-term debt, net, and finance leases were $2,514.2; total debt and finance leases before unamortized issuance costs were $2,532.5. The weighted-average debt interest rate was 4.88%, versus 4.58% at year-end 2022. Management said existing funds, operating cash generation, and financing access should fund operations for the foreseeable future.
Segments and material changes
- DSA: Q3 revenue rose 7.2% to $664.0; operating income increased 3.3% to $146.8, while margin slipped to 22.1% from 22.9%. Nine-month revenue increased 13.3% and operating income 27.6%. Growth was led by Safety Assessment; Discovery Services was weaker. DSA backlog declined to $2.60 billion from $3.15 billion at December 31, 2022.
- RMS: Q3 revenue rose 3.7% to $186.8, but operating income fell 21.1% to $28.3 and margin fell to 15.2% from 19.9%. Nine-month revenue increased 9.9%, while operating income declined 4.6%. Cost increases, Cell Solutions weakness, and timing of large-model sales affected profitability.
- Manufacturing: Q3 revenue fell 7.3% to $175.7 and operating income fell 16.5% to $26.3. Nine-month revenue declined 8.3% and operating income 62.4%; margin fell to 10.0% from 24.3%. The Avian divestiture, weaker Biologics Testing, higher Biologics operating costs, and an impairment charge weighed on results.
The company acquired SAMDI Tech for approximately $62.8 million in January 2023, adding drug-discovery screening capabilities to DSA. It sold Avian Vaccine Services in December 2022; the divestiture reduced nine-month 2023 Manufacturing revenue by $57.6 million versus the prior-year period.
Outlook, commentary, and risks
- Management described biopharmaceutical clients as more cautious with spending, while noting sequential improvement in DSA book-to-bill and study cancellation trends during Q3 and stable-to-improving biotech funding. No specific revenue or EPS guidance is stated in the supplied filing text.
- Restructuring actions across segments and geographies included workforce reductions and facility consolidation. The company expects approximately $40 million in annualized cost savings; nine-month restructuring costs were $21.3 million, including $14.3 million of asset impairment and other costs.
- DOJ and U.S. Fish and Wildlife Service investigations, and a separate SEC inquiry, concern non-human-primate sourcing, including Cambodia shipments. The company suspended future Cambodia-to-U.S. shipments pending additional procedures; related inventory carried a value of approximately $20 million. The outcome, timing, and potential fines or liabilities are uncertain.
- A putative securities class action filed in May 2023 alleges misleading disclosures about non-human-primate imports. The company intends to seek dismissal, but cannot reasonably estimate potential exposure or loss.
- Other watch items include higher interest rates on floating-rate debt, foreign-exchange exposure, and a proposed purchase of an additional 41% stake in a DSA supplier for a preliminary $143 million, subject to regulatory approval and closing conditions, with potential contingent payments.
Key facts for investors to verify
- Progress and financial impact of the DOJ, USFWS, and SEC inquiries, and the securities class action.
- Whether DSA backlog, bookings, and cancellations stabilize or recover, and the pace of client spending.
- Whether Manufacturing profitability improves after Avian’s sale and ongoing Biologics cost and impairment pressures.
- Delivery and timing of the expected $40 million annualized restructuring savings relative to implementation costs.
- Debt balances, variable-rate exposure, and cash generation; management’s liquidity statement is an expectation, not a guarantee.